Abstract:Here we report previously unknown mechanism of the response of human primary, skin‐derived, keratinocytes (KCs) to proinflammatory insults. We found that the Nuclear Transport Checkpoint Inhibitor (NTCI), our Investigational New Drug, arrested the nuclear import of STAT3, the transcription factor involved in allergic inflammation, and the NF‐kappa B, prototypical proinflammatory Stress‐Responsive Transcription Factor, in human KCs. Among the genes and cognate proteins suppressed by the NTCI, was the major driver of allergic reactions, Thymic Stromal Lymphopoietin (TSLP), that promotes Th2 response. Moreover, other core proinflammatory mediators, TNF alpha, IL1 beta, IL6, IL8 and CSF2, were also suppressed in human KCs, thereby blocking the pathogenesis of AD and other dermatoses. Background In the two common inflammatory skin diseases, Atopic Dermatitis (AD) and Psoriasis (Ps), keratinocytes (KCs) respond to immune insults through activation of proinflammatory transcription factors (TFs) and their translocation to the cell's nucleus. Therein, the TFs induce expression of genes encoding mediators of skin inflammation. The Nuclear Transport Checkpoint Inhibitors (NTCIs) were developed to regulate nuclear translocation of activated TFs, the essential step of inflammatory response. This new class of cell‐penetrating peptide therapeutics controls inflammation caused by allergic, autoimmune, metabolic, and microbial insults. In preclinical model of AD, the treatment with NTCI, cSN50.1 peptide, suppressed the expression of Thymic Stromal Lymphopoietin (TSLP), the key gene in the development of allergic inflammation, among the 15 genes silenced by the NTCI. Here, we report the mechanism of anti‐inflammatory action of NTCI in human skin‐derived KCs. Objectives We aimed to determine whether the NTCI treatment can protect human KCs from harmful inflammatory insults. Methods Human primary KCs were pretreated with NTCI and challenged with the mix of cytokines Tumour Necrosis Factor alpha (TNF‐α) and Interleukin (IL)‐17A, or with Phorbol 12‐Myristate 13‐Acetate (PMA), and analysed for nuclear content of TFs and the expression of genes encoding mediators of inflammation. Results The nuclear import of TFs, Nuclear Factor ĸB (NF‐ĸB) and Signal Transduction and Activator of Transcription 3 (STAT3), was inhibited in cells treated with NTCI. The expression of TSLP, along with genes encoding the core mediators of inflammation (TNF, IL1B, and IL6) was suppressed by NTCI. Noteworthy, NTCI silenced genes encoding Granulocyte‐Macrophage Colony‐Stimulating Factor (CSF2), and chemokine IL‐8 (CXCL8), responsible for skin infiltration by the eosinophils and other myelomonocytic cells. Conclusion The control of inflammatory response in human KCs by NTCI is attributed to the inhibition of nuclear import of proinflammatory TFs. The protection of human KCs by NTCI, adds new perspectives to the completed Phase two clinical trial of the NTCI (AMTX‐100 CF) for AD (NCT04313400).

Regulation of T Lymphocyte Functions through Calcium Signaling Modulation by Nootkatone

Effects of Antioxidant and Nitric Oxide on Chemokine Production in Tnf-Alpha-Stimulated Human Dermal Microvascular Endothelial Cells

KATP channel block inhibits the Toll-like receptor 2-mediated stimulation of NF-κB by suppressing the activation of Akt, mTOR, JNK and p38-MAPK

NQO1 mediates the anti-inflammatory effects of nootkatone in lipopolysaccharide-induced neuroinflammation by modulating the AMPK signaling pathway

Nootkatone Inhibits Acute and Chronic Inflammatory Responses in Mice

Nootkatone Protects Cartilage Against Degeneration in Mice by Inhibiting NF-κB Signaling Pathway

Nootkatone mitigates periodontal inflammation and reduces alveolar bone loss via Nrf2/HO-1 and NF-κB pathways in rat model of periodontitis

Nootkatone Supplementation Attenuates Carbon Tetrachloride Exposure-Induced Nephrotoxicity in Mice

Cycloolivil Isolated from Nardostachys jatamansi Inhibits TNF-α/IFN-γ-Induced Chemokine Production by Blocking NF-κB and JAK/STAT Activation in HaCaT Keratinocytes

Anti-Inflammatory Effect of Columbianetin on Lipopolysaccharide-Stimulated Human Peripheral Blood Mononuclear Cells

Chloranthalactone B covalently binds to the NACHT domain of NLRP3 to attenuate NLRP3-driven inflammation

Anti‐inflammatory control of human skin keratinocytes by targeting nuclear transport checkpoint

Modulation of Lymphocyte Potassium Channel KV1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin

Molecular Action Mechanisms of Two Novel and Selective Calcium Release-Activated Calcium Channel Antagonists.

T Cell Subset and Stimulation Strength-Dependent Modulation of T Cell Activation by Kv1.3 Blockers

Cryptotanshinone Attenuates Inflammatory Response of Microglial Cells Via the Nrf2/HO-1 Pathway

Nitidine Chloride Exerts Anti-Inflammatory Action by Targeting Topoisomerase I and Enhancing IL-10 Production.

High intracellular calcium amounts inhibit activation-induced proliferation of mouse T cells

Nootkatone Improves Chronic Unpredictable Mild Stress-Induced Depressive-Like Behaviors by Repressing NF-κB/NLRP3-Mediated Neuroinflammation

An L-type calcium channel blocker nimodipine exerts anti-fibrotic effects by attenuating TGF-β1 induced calcium response in an in vitro model of thyroid eye disease

The Role of Calcium–Calcineurin–NFAT Signaling Pathway in Health and Autoimmune Diseases